Presentations

Presentations

Feb 16, 2021

CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2020 Financial Results

Feb 05, 2021

CRISPR Therapeutics to Participate in the Guggenheim Healthcare Talks 2021 Oncology Day

Feb 01, 2021

CRISPR Therapeutics Announces the Appointment of Philippe Drouet as Chief Commercial Officer

Feb 01, 2021

CRISPR Therapeutics Corporate Presentation

Jan 04, 2021

CRISPR Therapeutics Corporate Presentation

Dec 14, 2020

CRISPR Therapeutics Receives Grant to Advance In Vivo CRISPR/Cas9 Gene Editing Therapies for HIV

Dec 09, 2020

Phase 1/2 CTX001™ Investor Update Presentation

Dec 06, 2020

2020 ASH Meeting and Exposition Presentation

Dec 05, 2020

CRISPR Therapeutics and Vertex Present New Data for Investigational CRISPR/Cas9 Gene-Editing Therapy, CTX001™ at American Society of Hematology Annual Meeting and Exposition, Together With Publication in the New England Journal of Medicine

Dec 01, 2020

CRISPR Therapeutics and Vertex to Host Investor Webcast to Review Data Presented at the 62nd American Society of Hematology Annual (ASH) Meeting and Exposition for Investigational CRISPR/Cas9 Gene-Editing Therapy CTX001™ in Sickle Cell Disease and Beta Th

Nov 24, 2020

CRISPR Therapeutics to Participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference

Nov 16, 2020

CRISPR Therapeutics to Participate in the Jefferies Virtual London Healthcare Conference

Nov 04, 2020

CRISPR/Cas9 Gene-Editing Therapy CTX001™ for Severe Hemoglobinopathies Accepted for Plenary Presentation at the 62nd American Society of Hematology (ASH) Meeting and Exposition

Oct 21, 2020

CRISPR Therapeutics Reports Positive Top-Line Results from Its Phase 1 CARBON Trial of CTX110™ in Relapsed or Refractory CD19+ B-cell Malignancies

Oct 21, 2020

Phase 1 CARBON Top-Line Data Presentation

Oct 07, 2020

CRISPR Therapeutics Congratulates Co-Founder Emmanuelle Charpentier on Receiving the 2020 Nobel Prize in Chemistry

Sep 29, 2020

CRISPR Therapeutics to Participate in Upcoming Investor Conferences

Sep 22, 2020

CRISPR Therapeutics and Vertex Pharmaceuticals Announce Priority Medicines (PRIME) Designation Granted by the European Medicines Agency (EMA) to CTX001™ for the Treatment of Sickle Cell Disease

Sep 03, 2020

CRISPR Therapeutics to Present at the Wells Fargo 2020 Virtual Healthcare Conference

Jul 30, 2020

CRISPR Therapeutics to Participate in Upcoming Investor Conferences

Jul 27, 2020

Jul 27, 2020

2019 Annual Report

Jun 30, 2020

CRISPR Therapeutics Announces Pricing of Public Offering of Common Shares

Jun 29, 2020

CRISPR Therapeutics Announces Proposed Offering of Common Shares

Jun 25, 2020

CRISPR Therapeutics Announces the Build-Out of New Cell Therapy Manufacturing Facility

Jun 17, 2020

2020 AACR II Virtual Meeting Poster: Functional and single-cell assessment of CRISPR-modified CAR-T cells from NSCLC patients and healthy donors

Jun 16, 2020

2020 AACR II Virtual Meeting Poster: Allogeneic CAR-T cell products containing 10 gene edits using CRISPR/Cas9 can retain full functionality in vivo and in vitro

Jun 15, 2020

2020 AACR II Virtual Meeting Poster: Allogeneic anti-PTK7 CAR-T cells for the treatment of solid tumors

Jun 14, 2020

2020 AACR II Virtual Meeting Poster: Targeting T cell lymphomas with CRISPR/Cas9-generated anti-CD70 allogeneic CAR-T cells

Jun 12, 2020

2020 European Hematology Association (EHA) Congress Presentation

May 11, 2020

2020 ASGCT Annual Meeting Poster: Multiplexing of up to 10 gene edits using CRISPR/Cas9 generate CAR-T cells with improved function

May 11, 2020

2020 ASGCT Annual Meeting Poster: Dual Guide CRISPR/Cas9 Editing of the CCR5 Gene Provides Complete Protection Against HIV in Humanized Mouse Models

May 11, 2020

2020 ASGCT Annual Meeting Poster: Insertion of Short Double-Stranded Oligonucleotides Using CRISPR/Cas9 as a Therapeutic Approach for Glycogen Storage Disease Type 1a

Apr 07, 2020

2019 PFIC Annual Information Statement

Apr 02, 2020

CRISPR Therapeutics Corporate Presentation

Mar 18, 2020

CRISPR Therapeutics Corporate Presentation

Nov 19, 2019

CRISPR Therapeutics Data Update Call Presentation

Nov 08, 2019

2019 Annual Meeting of The Society for Immunotherapy of Cancer (SITC) Poster: Single-cell RNA sequencing and functional assessment of healthy donor- and cancer patient-derived T and CAR-T cells

Sep 17, 2019

2019 European Association for the Study of Diabetes (EASD) Presentation

May 01, 2019

2019 ASGCT Annual Meeting Poster: CRISPR/Cas9 Gene Editing to Produce Multiple Allogeneic CAR-T Cell Candidates Showing Consistently High Potency, Durability, Lack of Alloreactivity, and Ability to Overcome Immune Suppression

Apr 02, 2019

2019 American Association for Cancer Research (AACR) Annual Meeting Poster: Targeting multiple solid tumor types with anti-CD70 allogeneic CAR-T cells

Apr 01, 2019

2019 American Association for Cancer Research (AACR) Annual Meeting Poster: Allogeneic CRISPR/Cas9 Gene-edited CAR-T Cells Targeting CD33 Show Potent Preclinical Activity Against AML Cells

Dec 01, 2018

2018 Annual Meeting of The American Society of Hematology (ASH) Poster: Preclinical Development of CTX120, an Allogeneic CAR-T Cell Product Candidate Targeting BCMA

Nov 09, 2018

2018 Annual Meeting of The Society for Immunotherapy of Cancer (SITC) Poster: CRISPR/Cas9 Enables the Efficient Production of Allogeneic CAR-T Cells Engineered to Contain Multiple Genome Edits to Enhance Therapeutic T Cell Function

May 15, 2018

2018 American Society of Gene & Cell Therapy (ASGCT) Annual Meeting Poster: Allogeneic CAR-T Cells with Multiple Therapeutically Favorable Edits Can Be Created Efficiently Using CRISPR/Cas9

Apr 16, 2018

2018 American Association for Cancer Research (AACR) Annual Meeting Poster: Allogeneic CRISPR Engineered Anti-CD70 CAR-T Cells Demonstrate Potent Preclinical Activity Against Both Solid and Hematological Cancer Cells

Apr 16, 2018

2018 American Association for Cancer Research (AACR) Annual Meeting Poster: Allogeneic Chimeric Antigen Receptor T Cells Targeting B Cell Maturation Antigen

You are now leaving the CRISPR Therapeutics website.

CRISPR Therapeutics is not responsible for the content or availability of third-party sites.